- Category: Pipeline
Pipeline
Preliminary data evaluates Astellas's RPE cell therapy for advanced GA
Presented at ARVO 2026, early 26- and 52-week safety phase 1b data from highlights notable visual gains in patients receiving ASP7317.
Pipeline
FDA agrees to special protocol assessment for Oculis’s phase 3 ON trial
Agreement on the PIONEER-1 study offers regulatory alignment on privosegtor’s registration path as a potential neuroprotective candidate.
Pipeline
Atsena releases positive XLRS interim data from LIGHTHOUSE study
Enrollment for Part C of the study is underway, with the company targeting a 2028 BLA submission for ATSN-201, an investigational gene therapy.
Pipeline
New SightGlass 24-month data shows DOT lenses significantly slow pediatric myopia progression
Unveiled at ARVO 2026, DOT lenses saved more than 1 D of myopic progression on average after 2 years among 6-to-10-year-old wearers.
Pipeline
Oculis reports final phase 3 patient visit for DME eye drops
Topline data on OCS-01 from DIAMOND program expected in June 2026 with the goal of supporting an NDA submission in Q4 2026.
Pipeline
MeiraGTx acquires J&J's XLRP investigational therapy
Deal includes all interests in botaretigene sparoparvovec (bota-vec); company plans to immediately file for global regulatory approval.
Pipeline
Belite Bio begins rolling NDA submission of oral tinlarebant for Stargardt
Full submission planned for Q2 2026, once-daily tablet has potential to become the first-ever treatment approved for this patient base.
Pipeline
Merck kicks off phase 2b/3 trial on tri-specific antibody for wet AMD
Merck initiates next phase of clinical testing in ophthalmology with two candidates targeting nAMD and DME.
Pipeline
Ocular Therapeutix releases additional phase 3 AXPAXLI data for wet AMD
Data from SOL-1 phase 3 data will become the basis of a planned NDA submission in near future.
Pipeline
FDA accepts Outlook Therapeutics' request over rejected wet AMD BLA
Company challenges decision on failed third submission package of ONS-5010 / LYTENAVA (bevacizumab-vikg), with a decision expected in May.
Pipeline
Aurion Biotech begins dosing in phase 3 trial on allogeneic cell therapy for CED
The ASTRA study kicks off evaluating AURN001, designed to regenerate corneal clarity and vision through an intracameral injection.
Pipeline
i-Lumen Scientific earns FDA IDE clearance for dry AMD trial
Biotech company is expanding the global i-SIGHT 2 pivotal trial evaluating its non-invasive bioelectric stimulation therapy as an in-office treatment.
Pipeline
Sydnexis's low-dose atropine shows strong phase 3 efficacy for pediatric myopia
Recent 3-year data from the STAR trial meets primary and secondary endpoints for SYD-101, including the greatest treatment benefits among younger myopes.
Pipeline
FDA grants RMAT designation to Ray Therapeutics' RP optogenetic therapy
RTx-015 is a single, IVT-administered therapeutic designed to restore vision by converting surviving neurons into photo-sensing cells.
Pipeline
FDA grants Orphan Drug Designation to SignaBlok's ROP therapy
TREM-1 inhibitor is designed to selectively target inflammation via a noninvasive delivery; company plans to report preclinical data at ARVO annual meeting.
Pipeline
Viridian releases phase 3 topline data on elegrobart for TED
REVEAL-1 meets primary goals, with the subcutaneous IGF-1R monoclonal antibody showing rapid and clinically meaningful reductions in proptosis and diplopia.
Pipeline
Kodiak reports positive phase 3 data on tarcocimab for DR
Topline findings from the GLOW2 trial indicate Zenkuda’s superiority over sham as company plans for a multi-indication FDA filing.
Pipeline
Lineage Cell Therapeutics launches new CED cell therapy program
Preclinical candidate COR1 is designed as an allogeneic source of corneal endothelial cells to replace damaged cells and restore corneal function.
Pipeline
Complement Therapeutics begins patient dosing in GA gene therapy trial
Opti-GAIN trial is evaluating a single subretinal injection of CTx-001, an AAV-based gene therapy modulating multiple pathways of the complement system.
Pipeline